GRM5-AS1: A Potential Drug Target and Biomarker (G100873989)

Target Name: GRM5-AS1

NCBI ID: G100873989

GRM5-AS1

Other Name(s): GRM5 antisense RNA 1

GRM5-AS1: A Potential Drug Target and Biomarker

Glycophosphorylase (GRM) family 5 (GRM5) is a group of enzymes that are involved in the metabolism of glycophosphorylase (GPL), a key enzyme in the glycosylation pathway. GPL is involved in the final step of the glycosylation pathway, which is the covalent binding of glucose to proteins. The covalent binding of glucose to proteins is a critical step in the development of diseases such as diabetes and cancer. Therefore, the inhibition of GRM5 can be an attractive strategy for the development of new treatments for these diseases.

GRM5 is a protein that is expressed in various cell types, including neurons, muscle cells, and red blood cells. It is a 21-kDa protein that consists of a catalytic active site, a regulatory region, and a C-terminal extension. The catalytic active site is the site of the active catalytic activity of the enzyme, and it is responsible for the catalytic mechanism of the GRM5 enzyme. The regulatory region is responsible for regulating the activity of the enzyme, and it includes a N-terminal region that contains a helix-loop structure. The C-terminal extension is the tail of the protein that contains a variety of functional groups that are involved in its stability and interactions with other proteins.

GRM5 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example,GRM5 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have also shown that GRM5 is involved in the development of cancer, including breast cancer and colorectal cancer. In addition,GRM5 has been shown to be involved in the regulation of cellular processes, including cell adhesion, migration, and apoptosis.

Based on these findings, it is clear that GRM5 is a potential drug target and biomarker for a variety of diseases. The inhibition of GRM5 activity could be an attractive strategy for the development of new treatments for these diseases. In addition, the study of GRM5 may also provide new insights into the biology of the glycosylation pathway and its regulation.

GRM5 has been shown to play a role in the regulation of glycosylation, which is the final step in the development of diseases. Glycosylation is the covalent binding of glucose to proteins, and it is a critical step in the development of diseases such as diabetes and cancer. Therefore, the inhibition of GRM5 activity could be an attractive strategy for the development of new treatments for these diseases.

In conclusion, GRM5-AS1 is a protein that has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The inhibition of GRM5 activity could be an attractive strategy for the development of new treatments for these diseases. Furthermore, the study of GRM5 may also provide new insights into the biology of the glycosylation pathway and its regulation. Further research is needed to fully understand the role of GRM5 in the development and progression of diseases.

Protein Name: GRM5 Antisense RNA 1

The "GRM5-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRM5-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets